Nasus Pharma (NSRX) Current Assets (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Current Assets came in at $4.9 million in Q4 2025, up 962.36% YoY from $457000.0 in Q4 2024, and up 1568.38% on a QoQ basis from $291000.0 in Q2 2025.
Nasus Pharma (NSRX) Current Assets (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Current Assets data on file, last reported at $4.9 million in Q4 2025.
- Quarterly Current Assets rose 962.36% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (up 962.36% YoY) and the FY2025 annual result came in at $4.9 million, up 962.36% from the prior year.
- Current Assets improved to $4.9 million in Q4 2025, from $291000.0 in the prior quarter.
- In the past five years, Current Assets ranged from a high of $4.9 million in Q4 2025 to a low of $291000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.10 Bn | 631.35 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 469.76 Bn | 463.19 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 375.02 Bn | 367.88 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 303.10 Bn | 295.41 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 257.62 Bn | 252.72 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 236.38 Bn | 222.39 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 159.63 Bn | 147.93 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Nasus Pharma | 31.72 Mn | 31.72 Mn | - | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.86 Mn |
| Jun 30, 2025 | 291,000.00 |
| Dec 31, 2024 | 457,000.00 |